The UK national guidelines for cerebrospinal £uid (CSF) bilirubin analysis in suspected subarachnoid haemorrhage (SAH) recommend measurement of the CSF bilirubin absorbance peak at 476 nm (the net bilirubin absorbance [NBA]). 1 An NBA 40.007 absorbance units (AU) is considered positive for xanthochromia. Because hyperbilirubinaemia (serum bilirubin concentrations X20 mmol/L) may result in protein-bound bilirubin in the CSF without an intra-cranial bleed, formulae incorporating serum bilirubin, CSF protein and serum total protein concentrations are recommended to adjust the NBA in such cases. The potential application of this adjusted NBA was assessed by an audit of patients in the Trent Region assessed for xanthochromia with hyperbilirubinaemia con¢rmed within 24 h of lumbar puncture between January 2000 and August 2004. The patients' NBA, serum bilirubin and total protein, and CSF protein concentrations were recorded if available.
There were 33 recorded hyperbilirubinaemia cases within 24 h of lumbar puncture for a xanthochromia screen. Serum bilirubin concentrations did not di¡er signi¢cantly between patients with NBAs 40.007AU (range 0.013--0.080AU) (n ¼ 7, median serum bilirubin concentration 22 mmol/L, interquartile range 21--29 mmol/L) and those with NBAs o0.007 AU (n ¼ 26, median 24 mmol/L, interquartile range 22--33 mmol/L; P ¼ 0.32, Mann--Whitney U test, SPSS Version 10.1). Su⁄cient data were available to calculate adjusted NBAs in 18 cases. One patient with a CSF protein concentration 41g/L was excluded. In all, 15 cases generated negative-adjusted NBAs (median À0.004 AU, range À0.002 to À0.017 AU). This observation raises concerns that the adjustment formula may generate adjusted NBA values p0.007 AU in hyperbilirubinaemic patients who have had SAH, leading to their inappropriate discharge from hospital.
In support of their recommendations, the guidelines cite studies that derived bilirubin correction formulae for xanthochromia investigations. These studies measured bilirubin concentrations directly 2 or used correction formulae with CSF absorbances measured at di¡erent wavelengths. 3--5 It is not clear that the results of these studies can be extrapolated to the current recommendations. It is also a matter of concern that the adjusted NBA incorporates four measurements, all subject to assay imprecision; combining these measurements in adjustment formulae compounds the imprecision.
We conclude that further evaluation is essential before NBA adjustment in hyperbilirubinaemic patients is introduced into clinical practice. We recommend that positive xanthochromia screens should simply be reported with a warning that false positives may occur in hyperbilirubinaemic patients. Attempts to generate an adjusted NBA suggest a spurious degree of accuracy, unjusti¢ed by the currently available evidence.
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